12 June 2024
Scancell Holdings
plc
("Scancell" or the
"Company")
Scancell Signs Agreement with
Major International Biotechnology Company to Evaluate an Antibody
in the Glymab® Portfolio
Exclusivity has been granted
to evaluate anti-glycan monoclonal antibody generated via
Scancell's proprietary GlyMab® platform.
Scancell Holdings plc (AIM: SCLP), the developer of novel oncology immunotherapies today
announces a major international biotechnology company, will
exclusively evaluate a Scancell investigational anti-glycan
monoclonal antibody for development of novel therapeutic products.
Under the terms of the agreement, Scancell has granted the company
seven months exclusivity for evaluation, which includes an $1M
exclusivity payment payable within 30 days.
Professor Lindy Durrant, Chief Executive Officer of Scancell,
said: "We are very pleased to
announce this agreement today with a leading international
biotechnology company. This is now the second anti-glycan
monoclonal antibody generated via our proprietary GlyMab® platform
to be evaluated, the first now being developed under a commercial
licence agreement. This provides further validation of the
potential of our antibody platform to create novel, differentiated
antibody products. Whilst the agreement is for an initial
exclusive evaluation period, there is an option to licence, and we
look forward to providing the market with any updates in due
course."
The Scancell anti-glycan monoclonal
antibody is a humanised antibody developed by Scancell, using its
novel anti-cancer GlyMab® platform. This is one of five monoclonal
antibodies currently in Scancell's antibody portfolio which
provides a rich reservoir of potential products for its in-house
clinical development and also for further deals.
About GlyMab®
Scancell is building a pipeline of
differentiated anti-cancer monoclonal antibodies ('mAbs') that
target sugar motifs rather than proteins. The Company currently has
five novel mAbs in early-stage development and has the potential to
use its unique methodology to identify many more mAbs against
glycan targets in the future. All cells are covered by a dense
layer of sugar structures, called glycans, which change when a
normal cell turns into a cancer cell. These glycan motifs that are
associated with tumour malignancies can be targeted by antibodies
such as the Company's GlyMab® portfolio. A robust portfolio of
patents and applications, as well as know-how, surround the GlyMab®
platform and generated drug candidates. The GlyMab® technology is
part of Scancell's antibody portfolio, joining AvidiMab®, a
technology that can be applied to all antibodies (regardless of the
technology used to generate them), enhancing their potency and
ability to directly kill tumour cells.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
-ENDS-
|
For
further information, please contact:
|
|
|
Scancell Holdings plc
Professor Lindy Durrant,
CEO
Dr Jean-Michel Cosséry,
Non-Executive Chairman
|
+44 (0) 20 3709 5700
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker
Nicholas Moore/Samira Essebiyea/Ben
Good (Healthcare Investment Banking)
Nick Harland (Corporate
Broking))
|
+44 (0) 20 7710 7600
|
|
|
|
|
WG
Partners LLP (Joint Broker)
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
+44 (0) 20 3705 9330
|
|
Panmure Gordon (UK) Limited (Joint Broker)
Freddy Crossley/Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate
Broking)
|
+44 (0) 20 7886 2500
|
|
ICR Consilium
Mary-Jane Elliott/ Angela Gray/
Lindsey Neville
|
+44 (0) 20 3709 5700
scancell@consilium-comms.com
|
About Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer and infectious disease. The Company is
building a pipeline of innovative products by utilising its four
technology platforms: Moditope® and
ImmunoBody® for vaccines and GlyMab® and
AvidiMab® for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope®
and ImmunoBody®) this includes citrullination
and homocitrullination of proteins, whereas its mAb portfolio
targets glycans or sugars that are added onto proteins and / or
lipids (GlyMab®) or enhances the potency of antibodies
and their ability to directly kill tumour cells
(AvidiMab®).
For further information about
Scancell, please visit: https://www.scancell.co.uk/